1
|
Sosa-Macías M, Fricke-Galindo I, Fariñas H, Monterde L, Ruiz-Cruz ED, Molina-Guarneros J, Tarazona-Santos E, Rodrigues-Soares F, Galaviz-Hernández C, Peñas-Lledó E, Moya G, Lara-Riegos J, Terán E, Hernández I, Ramírez-Roa R, Altamirano-Tinoco C, López-López M, García-Ortiz JE, LLerena A. Pharmacogenetics: ethnicity, treatment and health in Latin American populations. Pharmacogenomics 2023; 24:489-492. [PMID: 37529900 DOI: 10.2217/pgs-2023-0098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/03/2023] Open
Abstract
The Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF) studies Latin American populations to benefit from the implementation of personalized medicine. Since 2006, it has studied ethnicity to apply pharmacogenetics knowledge in autochthonous populations of Latin America, considering ancestral medicine. The meeting 'Pharmacogenetics: ethnicity, Treatment and Health in Latin American Populations' was held in Mexico City, Mexico, and presented the relevance of RIBEF collaboration with Latin American researchers and the governments of Mexico, Spain and the Autonomous Community of Extremadura. The results of 17 years of uninterrupted work by RIBEF, the Declaration of Mérida/T'Hó and the call for the Dr José María Cantú Award for studies focused on the pharmacogenetics of native populations in Latin America were presented.
Collapse
Affiliation(s)
- Martha Sosa-Macías
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- IPN Instituto Politécnico Nacional CIIDIR-Unidad Durango, Mexico
| | - Ingrid Fricke-Galindo
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
| | - Humberto Fariñas
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- INUBE Instituto Universitario de Investigación Biosanitaria de Extremadura, University of Extremadura, Extremadura, Spain
- SIFF Ibero American Society of Pharmacogenetics & Pharmacogenomics
| | | | | | - Juan Molina-Guarneros
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UNAM Universidad Nacional Autónoma de Mexico, Mexico City, Mexico
| | - Eduardo Tarazona-Santos
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UFMG Universidade Federal de Minas Gerais, Instituto de Ciencias Biológicas, Belo Horizonte, Brazil
- UPCH Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Fernanda Rodrigues-Soares
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UFTM Universidade Federal do Triangulo Mineiro, Uberaba, Brazil
| | - Carlos Galaviz-Hernández
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- IPN Instituto Politécnico Nacional CIIDIR-Unidad Durango, Mexico
| | - Eva Peñas-Lledó
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- INUBE Instituto Universitario de Investigación Biosanitaria de Extremadura, University of Extremadura, Extremadura, Spain
| | - Graciela Moya
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UCA Universidad Católica Argentina, Buenos Aires, Argentina
| | - Julio Lara-Riegos
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UADY Universidad Autónoma de Yucatán, Mexico
| | - Enrique Terán
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- USFQ Universidad San Francisco de Quito, Ecuador
| | - Isabel Hernández
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- PUCE Pontificia Universidad Católica del Ecuador, Ecuador
| | - Ronald Ramírez-Roa
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- SIFF Ibero American Society of Pharmacogenetics & Pharmacogenomics
| | - Catalina Altamirano-Tinoco
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UNAN Universidad Nacional Autónoma de Nicaragua-León, Nicaragua
| | - Marisol López-López
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- UAM Universidad Autónoma Metropolitana, Mexico City, Mexico
| | - José Elías García-Ortiz
- CIBO, Centro de Investigación Biomédica de Occidente-IMSS, Guadalajara, Mexico
- RELAGH Latin American Network of Human Genetics
| | - Adrián LLerena
- RIBEF Ibero American Network of Pharmacogenetics & Pharmacogenomics
- INUBE Instituto Universitario de Investigación Biosanitaria de Extremadura, University of Extremadura, Extremadura, Spain
| |
Collapse
|
2
|
de Andrés F, Altamirano-Tinoco C, Ramírez-Roa R, Montes-Mondragón CF, Dorado P, Peñas-Lledó EM, LLerena A. Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. Pharmacogenomics J 2020; 21:140-151. [PMID: 33024249 DOI: 10.1038/s41397-020-00190-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 08/17/2020] [Accepted: 09/23/2020] [Indexed: 12/19/2022]
Abstract
Interethnic variability in the drug-metabolizing capacity of CYP450 enzymes may lead to discrepancies in the relationship between genotypes and phenotypes worldwide. The present study was aimed to analyze for the first time whether there is a relationship between clinically relevant CYP450 genetic polymorphisms and their drug oxidation capacity (metabolic phenotype) in a population of healthy Nicaraguan volunteers. Two hundred and twelve participants were genotyped for CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and their actual metabolic phenotype (evaluated by the Metabolic Ratio, MR) was analyzed by using the CEIBA cocktail approach. The results showed the wide interindividual variability in all the studied enzymes and a significant difference (p < 0.004) in the activity of CYP1A2 between male and female subjects. The number of CYP2C19 (p < 0.0001) and CYP2D6 (p < 0.0001) active alleles were shown inversely correlated with their corresponding MR, although there were marked genotype-phenotype discrepancies. There was an actual enzyme capacity overlapping (MR) between genotypically Poor (gPMs) and Extensive Metabolizers (gEMs) of 3.14% subjects for CYP2D6 and 0.94% for CYP2C9. Similarly, there was an overlapping for metabolic phenotypes of 11.48% of genotypically ultrarapid metabolizers (gUMs) for CYP2C19 and 2.09% for CYP2D6 and gEMs. Therefore, the current approach for metabolic phenotype prediction based just on genotype does not predict properly for all individuals within this Nicaraguan Mestizo population, thus representing a potential barrier for the clinical implementation of personalized medicine in this region. However, it is necessary to improve the prediction of phenotype from genotype in order to improve the pharmacogenetic implementation in populations with specific ethnic backgrounds.
Collapse
Affiliation(s)
- Fernando de Andrés
- INUBE Extremadura Biosanitary University Research Institute, CICAB Clinical Research Centre, Badajoz University Hospital; University of Extremadura, Badajoz, Spain.,RIBEF Ibero American Network of Pharmacogenetics and Pharmacogenomics, León, Nicaragua
| | - Catalina Altamirano-Tinoco
- RIBEF Ibero American Network of Pharmacogenetics and Pharmacogenomics, León, Nicaragua.,UNAN Universidad Nacional Autónoma de Nicaragua, Facultad de Ciencias Médicas, León, Nicaragua
| | - Ronald Ramírez-Roa
- RIBEF Ibero American Network of Pharmacogenetics and Pharmacogenomics, León, Nicaragua. .,UNAN Universidad Nacional Autónoma de Nicaragua, Facultad de Ciencias Médicas, León, Nicaragua.
| | | | - Pedro Dorado
- INUBE Extremadura Biosanitary University Research Institute, CICAB Clinical Research Centre, Badajoz University Hospital; University of Extremadura, Badajoz, Spain.,RIBEF Ibero American Network of Pharmacogenetics and Pharmacogenomics, León, Nicaragua.,Faculty of Medicine, University of Extremadura, Badajoz, Spain
| | - Eva M Peñas-Lledó
- INUBE Extremadura Biosanitary University Research Institute, CICAB Clinical Research Centre, Badajoz University Hospital; University of Extremadura, Badajoz, Spain.,RIBEF Ibero American Network of Pharmacogenetics and Pharmacogenomics, León, Nicaragua.,Faculty of Medicine, University of Extremadura, Badajoz, Spain
| | - Adrián LLerena
- INUBE Extremadura Biosanitary University Research Institute, CICAB Clinical Research Centre, Badajoz University Hospital; University of Extremadura, Badajoz, Spain. .,RIBEF Ibero American Network of Pharmacogenetics and Pharmacogenomics, León, Nicaragua. .,Faculty of Medicine, University of Extremadura, Badajoz, Spain. .,CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|